UY39313A - Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire - Google Patents
Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aireInfo
- Publication number
- UY39313A UY39313A UY0001039313A UY39313A UY39313A UY 39313 A UY39313 A UY 39313A UY 0001039313 A UY0001039313 A UY 0001039313A UY 39313 A UY39313 A UY 39313A UY 39313 A UY39313 A UY 39313A
- Authority
- UY
- Uruguay
- Prior art keywords
- treatment
- airborne
- viral infections
- cov
- buffering compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención hace referencia a una composición amortiguadora que tiene un pH de 6,7 a 7,9 a una temperatura de 37 °C para su uso en el tratamiento, el tratamiento profiláctico o la mejora de una infección viral transmitida por el aire, o para su uso en la reducción de la replicación viral en un sujeto infectado con, o expuesto a, un virus transmitido por el aire. Los virus transmitidos por el aire incluyen los virus de ARN, tales como los coronavirus, por ejemplo, MERS-CoV, SARS-CoV y SARS-CoV-2.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2010271.1A GB202010271D0 (en) | 2020-07-03 | 2020-07-03 | Viral infections |
GBGB2013976.2A GB202013976D0 (en) | 2020-09-05 | 2020-09-05 | Viral infections |
GBGB2018446.1A GB202018446D0 (en) | 2020-11-24 | 2020-11-24 | Viral infections |
GBGB2018571.6A GB202018571D0 (en) | 2020-11-25 | 2020-11-25 | Viral infections |
GBGB2020320.4A GB202020320D0 (en) | 2020-12-21 | 2020-12-21 | Viral infections |
GBGB2105509.0A GB202105509D0 (en) | 2021-04-18 | 2021-04-18 | Viral infections |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39313A true UY39313A (es) | 2022-01-31 |
Family
ID=76920766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039313A UY39313A (es) | 2020-07-03 | 2021-07-02 | Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230301948A1 (es) |
EP (1) | EP4175503A1 (es) |
JP (1) | JP2023531568A (es) |
AU (1) | AU2021298896A1 (es) |
BR (1) | BR112022026880A2 (es) |
IL (1) | IL299572A (es) |
MX (1) | MX2023000242A (es) |
TW (1) | TW202207952A (es) |
UY (1) | UY39313A (es) |
WO (1) | WO2022003200A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023137159A2 (en) * | 2022-01-13 | 2023-07-20 | Noor Brands Company, Llc | Spray compositions and methods of use |
CN114904006B (zh) * | 2022-05-27 | 2023-10-17 | 中农威特生物科技股份有限公司 | 一种***抗原热稳定性保护剂及其制备方法和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5711918A (en) * | 1980-06-24 | 1982-01-21 | Tokai Daigaku | Remedy for herpes virus infection in human bodies |
FR2616065A1 (fr) * | 1987-06-02 | 1988-12-09 | Pabst Jean Yves | Aerosol pharmaceutique a base d'ammonium quaternaires |
US5863563A (en) * | 1994-10-20 | 1999-01-26 | Alphagene Inc. | Treatment of pulmonary conditions associated with insufficient secretion of surfactant |
US20020006961A1 (en) * | 1999-05-14 | 2002-01-17 | Katz Stanley E. | Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
ES2350330T3 (es) * | 2000-06-07 | 2011-01-21 | Watson Pharmaceuticals, Inc. | Tratamiento de la hiperactividad del músculo liso con (r)-oxibutinina y (r)-desetiloxibutinina. |
US20130156871A1 (en) * | 2011-12-20 | 2013-06-20 | Water Pik, Inc. | Nasal Wash Solution |
US20150231095A1 (en) * | 2013-04-18 | 2015-08-20 | Steven A. Melman | Antimicrobial compositions and uses therefore |
WO2015073648A1 (en) | 2013-11-13 | 2015-05-21 | Thomas Daly | Biological buffers with wide buffering ranges |
WO2017212422A1 (en) * | 2016-06-08 | 2017-12-14 | Novartis Consumer Health Sa | Topical compositions comprising carbomer for the treatment and prevention of viral infections and allergic conditions |
US11013687B1 (en) * | 2020-06-08 | 2021-05-25 | Amcyte Pharma, Inc. | Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2 |
-
2021
- 2021-07-02 UY UY0001039313A patent/UY39313A/es unknown
- 2021-07-02 US US18/013,856 patent/US20230301948A1/en active Pending
- 2021-07-02 AU AU2021298896A patent/AU2021298896A1/en active Pending
- 2021-07-02 BR BR112022026880A patent/BR112022026880A2/pt not_active Application Discontinuation
- 2021-07-02 JP JP2023523677A patent/JP2023531568A/ja active Pending
- 2021-07-02 IL IL299572A patent/IL299572A/en unknown
- 2021-07-02 EP EP21742078.5A patent/EP4175503A1/en active Pending
- 2021-07-02 TW TW110124423A patent/TW202207952A/zh unknown
- 2021-07-02 MX MX2023000242A patent/MX2023000242A/es unknown
- 2021-07-02 WO PCT/EP2021/068425 patent/WO2022003200A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2022003200A1 (en) | 2022-01-06 |
MX2023000242A (es) | 2023-03-03 |
JP2023531568A (ja) | 2023-07-24 |
US20230301948A1 (en) | 2023-09-28 |
TW202207952A (zh) | 2022-03-01 |
AU2021298896A1 (en) | 2023-02-16 |
IL299572A (en) | 2023-02-01 |
BR112022026880A2 (pt) | 2023-03-14 |
EP4175503A1 (en) | 2023-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022015415A2 (es) | Aplicación antiviral de análogo de nucleósido o formulación combinada que contiene análogo de nucleósido | |
CL2020000685A1 (es) | Nucleósidos sustituidos, nucleótidos y análogos de estos. | |
GT201300093A (es) | Compuestos antivirales | |
UY39313A (es) | Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire | |
BR112018009009A8 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
UY34983A (es) | Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas | |
CL2016000805A1 (es) | Nucleósidos sustituidos, nucleótidos y análogos de los mismos. | |
BR112022026321A2 (pt) | Análogos de 1'-ciano nucleosídeo e usos dos mesmos | |
CO6390076A2 (es) | Inhibidores de hcv ns5a | |
BRPI0716483B8 (pt) | compostos inibidores do vírus da hepatite c e composição farmacêutica que os compreende | |
BR112018071048A2 (pt) | combinações e métodos que compreendem um inibidor da montagem de capsídeos | |
WO2022217154A3 (en) | Modified nucleosides and nucleotides analogs as antiviral agents for corona and other viruses | |
UY29915A1 (es) | Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina | |
BR112022017243A2 (pt) | Lactoferrina para uso oral com ação antiviral | |
BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
CO2023017300A2 (es) | Compuestos moduladores de diacilglicerol quinasa | |
DOP2014000034A (es) | Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv) | |
BR112015005347A2 (pt) | composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids | |
CL2015003358A1 (es) | Compuestos derivados de nucleósidos 4'-azido-3'-desoxi-3'-fluoro sustituidos; composición farmacéutica que comprende a dichos compuestos y el uso de los mismos para tratar una infección del virus de la hepatitis c (hcv). | |
BR112019006802A2 (pt) | compostos e métodos para diagnóstico e tratamento de infecções virais | |
WO2020035609A3 (en) | Immunogenic compositions and uses thereof | |
MX2020003473A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
CL2021002307A1 (es) | Uso de virus oncolíticos para el tratamiento del cáncer | |
AR074483A1 (es) | Composiciones, metodos y usos para inducir al crecimiento viral | |
BR112013007700A2 (pt) | formas em estado sólido de um potente inibidor de hcv |